Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 663 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, February 18th, Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.56, for a total value of $362,246.40.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded down $6.45 during mid-day trading on Tuesday, hitting $250.00. 910,244 shares of the stock traded hands, compared to its average volume of 691,530. The company has a market cap of $32.25 billion, a PE ratio of -95.42 and a beta of 0.35. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a 50 day simple moving average of $254.04 and a two-hundred day simple moving average of $263.44.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALNY. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth $1,045,822,000. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $577,941,000. Capital Research Global Investors raised its position in shares of Alnylam Pharmaceuticals by 32.9% in the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after acquiring an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after acquiring an additional 1,245,195 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock worth $89,100,000 after acquiring an additional 315,182 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Scotiabank lowered their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Finally, StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.